# US 9,750,778 B2 · Terminalia chebula and Terminalia bellirica extracts for inhibition of xanthine oxidase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,750,778 B2
- Document ID: US9750778B2
- Status: Granted
- Kind: B2
- Application number: 14/459,046
- Filed: 2014-08-13
- Published: 2015-02-19
- Granted: 2017-09-05
- Earliest claimed: 2013-08-13
- Assignees: Natreon, Inc.
- Applicants: Natreon, Inc.
- Inventors: Sanyasi R. Kalidindi
- Web page: https://patentgrep.com/patent/US9750778B2

## CPC

- A61K 36/185: Magnoliopsida (dicotyledons)
- A61K 36/61: Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 39/06: Free radical scavengers or antioxidants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions containing extracts of Terminalia chebula and Terminalia bellerica, or combinations thereof and methods for treatment of uricemia, hyperuricemia, and gout in a human subject are provided.

## Claims

### Claim 1

A method of treating a free radical-induced disease in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a composition consisting essentially of an aqueous extract of Terminalia bellirica,
wherein the aqueous extract comprises at least 15% of one or more bioactive low molecular weight hydrolyzable tannins selected from the group consisting of chebulinic acid and chebulagic acid based on the total weight of the extract,
wherein the administered composition inhibits xanthine oxidase activity, and
wherein the free radical-induced disease is selected from the group consisting of gout, uricemia, and hyperuricemia.

### Claim 2 (depends on 1)

The method of claim 1, wherein the aqueous extract composition comprises not less than about 2% by weight of chebulinic acid based on the total weight of the extract, not less than about 2% by weight of chebulagic acid based on the total weight of the extract, and not less than about 10% by weight other low molecular weight hydrolyzable tannoids based on the total weight of the extract.

### Claim 3 (depends on 2)

The method of claim 2, wherein the composition has an effective dose (ED50) of about 5 μg/ml for inhibition of xanthine oxidase.

### Claim 4

A method of treating hyperuricemia in a human individual in need thereof comprising orally administering to the human individual a therapeutically effective amount of a composition consisting essentially of an aqueous extract of Terminalia bellirica,
wherein the aqueous extract comprises at least 15% of one or more bioactive low molecular weight hydrolyzable tannins selected from the group consisting of chebulinic acid and chebulagic acid based on the total weight of the extract; and
wherein the serum uric acid level in the individual is lowered.

### Claim 5 (depends on 4)

The method of claim 4, wherein serum uric acid is lowered to less than about 6.8 mg/dl.

### Claim 6 (depends on 4)

The method of claim 4, wherein serum uric acid is lowered to less than about 6.0 mg/dl.

### Claim 7 (depends on 4)

The method of claim 4, wherein the aqueous extract comprises not less than about 2% by weight of chebulinic acid based on the total weight of the extract, not less than about 2% by weight of chebulagic acid based on the total weight of the extract, and not less than about 10% by weight other low molecular weight hydrolyzable tannoids based on the total weight of the extract.

### Claim 8 (depends on 7)

The method of claim 7, wherein the composition is provided in a daily dosage range of from about 250 mg to about 2000 mg.

### Claim 9 (depends on 7)

The method of claim 7, wherein the composition is provided in a daily dosage range of from about 500 mg to about 1000 mg.

### Claim 10 (depends on 9)

The method of claim 9, wherein serum uric acid is lowered to less than about 6.8 mg/dl.

### Claim 11 (depends on 9)

The method of claim 9, wherein serum uric acid is lowered to less than about 6.0 mg/dl.